BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Sloot, Zager, Kedchadkar...Weber, Sondak, Gibney. Melanoma Res. 2/2016.
Adjuvant treatment provides positive benefits! Here's more adjuvant trial results: From my NED nivo/Opdivo trial as well as one with ipi!
Here are a few amazing quotes:
From the Nivo trial (published Dec 2014!!!) ~ "Our data suggest that nivo is clinically active in resected stage IIIC/IV melanoma, based on low rate of relapse (10 of 33), impressive relapse-free survival - estimated RFS of 47.1 months, and median overall survival not yet reached with over 32 months of follow up."
And this from the ipi ~ "Adjuvant ipi significantly improved recurrence-free survival for patients with completely resected high-risk stage III melanoma."
What are we waiting on??? Come on researchers! FDA?!!! Drug companies????!!!! Hang in there, Ratties. You rock! - c